OKYO Pharma’s OK-101 Advances in Phase 2 Trials for Dry Eye and Corneal Pain
OKYO Pharma advances OK-101 for dry eye and neuropathic corneal pain with positive Phase 2 results.
The biopharmaceutical business OKYO Pharma Limited is making progress in creating therapeutics for two illnesses that now lack viable treatments: neuropathic corneal pain (NCP) and dry eye disease (DED). OK-101, their flagship candidate, has demonstrated encouraging outcomes in Phase 2 studies, with notable reductions in DED symptoms along with a good safety profile. In addition, the business is getting ready to start a Phase 2 trial for OK-101 in the treatment of NCP, emphasising the drug's potential to meet unmet ophthalmic medical requirements.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Novo Nordisk Firma un Accordo da $2.6B con Hengrui per GLP-1 Orale
Discussion